See Important Safety Information, including Boxed Warning. How AUSTEDO XR® (deutetrabenazine) extended-release tablets may help.

See Prescribing Information, including Boxed Warning. Find information for healthcare professionals about once-daily AUSTEDO XR.

Aug 20, 2025 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more

Nov 7, 2025 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting …

2 days ago · New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

4 days ago · PARSIPPANY, N.J., and TEL AVIV, Israel – – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the …

3 days ago · Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful …

FULL PRESCRIBING INFORMATION WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE AUSTEDO XR and AUSTEDO can increase the risk of …

APPROVED USE AUSTEDO XR® (deutetrabenazine) extended-release tablets and AUSTEDO® (deutetrabenazine) tablets are prescription medicines that are used to treat the movements in …

Nov 6, 2025 · Tardive dyskinesia is best treated by first discontinuing the causative medication, if possible, and then using FDA-approved VMAT2 inhibitors, such as valben...